EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE

被引：0

作者：

Skljarevski, V. ^{[1
]}

Oakes, T. ^{[1
]}

Ferguson, M. ^{[2
]}

Zhang, Q. ^{[3
]}

Martinez, J. ^{[1
]}

Johnson, K. ^{[4
]}

Schacht, A. ^{[5
]}

Due, M. ^{[6
]}

Goadsby, P. ^{[7
]}

Dodick, D. ^{[8
]}

机构：

[1] Eli Lilly & Co, Pain Team Med, Indianapolis, IN 46285 USA

[2] Eli Lilly & Co, Clin Operat, Scarborough, ON, Canada

[3] Eli Lilly & Co, Stat Neurosci, Indianapolis, IN 46285 USA

[4] Eli Lilly & Co, Pain Migraine, Indianapolis, IN 46285 USA

[5] Eli Lilly & Co, Elanco, Indianapolis, IN 46285 USA

[6] Eli Lilly & Co, Global Sci Commun, Indianapolis, IN 46285 USA

[7] Kings Coll London, Dept Neurol, London, England

[8] Mayo Clin, Dept Neurol, Phoenix, AZ USA

来源：

CEPHALALGIA | 2016年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EHMTC-0110

引用

下载

页码：42 / 42

页数：1

共 50 条

[1] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
Oakes, T.
Zhang, Q.
Ferguson, M.
Skljarevski, V
Martinez, J. M.
Johnson, K. W.
Schacht, A. L.
Due, M. R.
Goadsby, P.
Dodick, D. W.
HEADACHE, 2016, 56 : 68 - 68
[2] Evaluation of Efficacy and Safety of LY2951742 in Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Dose-Ranging Studies in Patients With Migraine
Iyengar, Smriti
Dodick, David W.
Goadsby, Peter J.
Zhang, Qi
Ferguson, Margaret B.
Oakes, Tina M.
Martinez, James M.
Due, Michael R.
Schacht, Aaron L.
Skljarevski, Vladimir
Johnson, Kirk W.
NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S381 - S382
[3] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Dodick, D.
Goadsby, P. J.
Spierings, E. L.
Scherer, J.
Sweeney, S.
Grayzel, D.
HEADACHE, 2014, 54 (08): : 1430 - 1430
[4] CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
Goadsby, P.
Dodick, D.
Spierings, E.
Scherer, J.
Sweeney, S.
Grayzel, D.
JOURNAL OF HEADACHE AND PAIN, 2014, 15
[5] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Dodick, David
Goadsby, Peter
Spierings, Egilius
Scherer, Joel
Sweeney, Steven
Grayzel, David
NEUROLOGY, 2014, 83 (02) : E39 - E40
[6] Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Stohl, William
Merrill, Joan T.
McKay, James D.
Lisse, Jeffrey R.
Zhong, Z. John
Freimuth, William W.
Genovese, Mark C.
JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) : 579 - 589
[7] EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
P Goadsby
D Dodick
E Spierings
J Scherer
S Sweeney
D Grayzel
The Journal of Headache and Pain, 2014, 15
[8] Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
Dodick, David W.
Goadsby, Peter J.
Spierings, Egilius L. H.
Scherer, Joel C.
Sweeney, Steven P.
Grayzel, David S.
LANCET NEUROLOGY, 2014, 13 (09): : 885 - 892
[9] A dose-ranging study of midazolam for postoperative sedation of patients: A randomized, double-blind, placebo-controlled trial
Hanaoka, K
Namiki, A
Dohi, S
Koga, Y
Yuge, O
Kayanuma, Y
Hidaka, K
Kusunoki, T
CRITICAL CARE MEDICINE, 2002, 30 (06) : 1256 - 1260
[10] DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF ADENOSINE IN PATIENTS WITH SUPRAVENTRICULAR TACHYCARDIA
CARUSO, AC
MILES, WM
KLEIN, LS
ZIPES, DP
CLINICAL RESEARCH, 1989, 37 (04): : A874 - A874

← 1 2 3 4 5 →